Combination of peroxisome proliferator-activated receptor α/γ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion

Wei,Jinru; Tang,Quan; Liu,Lijuan; Bin,Jianbin

doi:10.3892/etm.2013.891

Combination of peroxisome proliferator-activated receptor α/γ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion

Authors:
- Jinru Wei
- Quan Tang
- Lijuan Liu
- Jianbin Bin
View Affiliations

Affiliations: Department of Cardiology, The Fifth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545006, P.R. China
Published online on: January 10, 2013 https://doi.org/10.3892/etm.2013.891
Pages: 783-788

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease (CVD). Peroxisome proliferator-activated receptors (PPARs) play an important role in the regulation of energy homeostasis. Therefore, we aimed to observe the effects of combined PPARα/γ agonists on T2DM patients with coronary artery disease (CAD). Patients were randomly divided into a rosiglitazone (RSG) group (n=20), a bezafibrate (BEZ) group (n=20), a combination of RSG and BEZ group (n=20) and a control group (n=20). Plasma C-reactive protein (CRP) and monocyte chemoattractant protein-1 (MCP-1) were measured by enzyme-linked immunosorbent assay before and 12 weeks after treatment. Fasting blood glucose (FBG), fasting insulin, insulin resistance index (IRI), hemoglobin A1c (HbA1c), lipid levels and body mass index were also investigated. At the end of the treatment, FBG, insulin, IRI, HbA1c and triglyceride levels decreased and the level of high-density lipoprotein cholesterol increased in the RSG, BEZ and combination groups. A decrease in low-density lipoprotein cholesterol was only observed in the combination group. Although the total cholesterol levels in all groups decreased, no significant difference was noted. The levels of CRP and MCP-1 were reduced in patients in the RSG, BEZ and combination groups. In addition, RSG, BEZ and the combination of RSG and BEZ also inhibited MCP-1 secretion. The combination of RSG and BEZ was more efficient than RSG or BEZ alone in downregulating cytokines. In conclusion, our results suggest that a combination of RSG and BEZ may be more efficient than RSG or BEZ alone in the treatment of T2DM patients with CAD.

View Figures

View References

1.	Haffner SM, Lehto S, Rönnemaa T, Pyörälä K and Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:229–234. 1998. View Article : Google Scholar : PubMed/NCBI
2.	Shirani J and Dilsizian V: Screening asymptomatic patients with type 2 diabetes mellitus for coronary artery disease: does it improve patient outcome? Curr Cardiol Rep. 12:140–146. 2010. View Article : Google Scholar
3.	Desvergne B and Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 20:649–688. 1999.PubMed/NCBI
4.	Becker J, Delayre-Orthez C, Frossard N and Pons F: Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol. 20:429–447. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Calkin AC and Thomas MC: PPAR agonists and cardiovascular disease in diabetes. PPAR Res. 2008:2454102008. View Article : Google Scholar : PubMed/NCBI
6.	Inoue I, Goto S, Mizotani K, et al: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 67:863–876. 2000.
7.	Staels B, Koenig W, Habib A, et al: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 393:790–793. 1998. View Article : Google Scholar : PubMed/NCBI
8.	Turay J, Grniaková V and Valka J: Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate. Drugs Exp Clin Res. 26:83–88. 2000.PubMed/NCBI
9.	Marx N, Sukhova G, Murphy C, Libby P and Plutzky J: Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol. 153:17–23. 1998.
10.	Jiang C, Ting AT and Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:82–86. 1998. View Article : Google Scholar : PubMed/NCBI
11.	Delerive P, De Bosscher K, Besnard S, et al: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 274:32048–32054. 1999. View Article : Google Scholar
12.	Chakrabarti R, Vikramadithyan RK, Misra P, et al: Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 140:527–537. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Mittra S, Sangle G, Tandon R, et al: Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema? Br J Pharmacol. 150:480–487. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA and Thomas MC: Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis. 195:17–22. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Calkin AC, Cooper ME, Jandeleit-Dahm KA and Allen TJ: Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia. 49:766–774. 2006. View Article : Google Scholar
16.	Calkin AC, Forbes JM, Smith CM, et al: Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol. 25:1903–1909. 2005. View Article : Google Scholar
17.	Nissen SE, Wolski K and Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 294:2581–2586. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Tordjman K, Bernal-Mizrachi C, Zemany L, et al: PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest. 107:1025–1034. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Mardones P, Pilon A, Bouly M, et al: Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J Biol Chem. 278:7884–7890. 2003. View Article : Google Scholar : PubMed/NCBI
20.	Berger J and Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 53:409–435. 2002. View Article : Google Scholar : PubMed/NCBI
21.	Saha SA, Kizhakepunnur LG, Bahekar A and Arora RR: The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J. 154:943–953. 2007. View Article : Google Scholar
22.	Zeng X, Dai J, Remick DG and Wang X: Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ Res. 93:311–320. 2003. View Article : Google Scholar
23.	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–419. 1985. View Article : Google Scholar : PubMed/NCBI
24.	Laakso M: Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes. 48:937–942. 1999. View Article : Google Scholar : PubMed/NCBI
25.	Tenenbaum A, Motro M, Fisman EZ, et al: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 109:2197–2202. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Jones IR, Swai A, Taylor R, Miller M, Laker MF and Alberti KG: Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care. 13:855–863. 1990. View Article : Google Scholar : PubMed/NCBI
27.	Sobel BE: Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med. 120(9 Suppl 2): S3–S11. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Liuzzo G, Goronzy JJ, Yang H, et al: Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 101:2883–2888. 2000. View Article : Google Scholar : PubMed/NCBI
29.	Chinetti G, Fruchart JC and Staels B: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol. 90(Suppl 3): 125–132. 2001.PubMed/NCBI
30.	Wang G, Wei J, Guan Y, Jin N, Mao J and Wang X: Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism. 54:590–597. 2005. View Article : Google Scholar
31.	Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF and Lee YT: Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis. 170:315–323. 2003. View Article : Google Scholar : PubMed/NCBI
32.	Han SH, Quon MJ and Koh KK: Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension. 46:1086–1092. 2005. View Article : Google Scholar : PubMed/NCBI
33.	Mohanty P, Aljada A, Ghanim H, et al: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 89:2728–2735. 2004. View Article : Google Scholar : PubMed/NCBI